AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26515411 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation treatment with a single 8 Gy dose for the worst group identified.
Number of subjects: 811
Study 26515411 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst group identified from the survival prediction model.
Number of subjects: 811
Study 25325203 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimen: 1 ciprofloxacin 500 mg tablet and 2 metronidazole 250 mg tablets taken 2 hours before biopsy
Number of subjects: 160
Study 25325203 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose regimen: ciprofloxacin and metronidazole every 12 hours from 3 days before biopsy
Number of subjects: 160
Study 25325203 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimen
Number of subjects: 160
Study 25325203 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose regimen
Number of subjects: 160
Study 25325203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 160
Study 22691922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) 43 g daily for 12 weeks
Number of subjects: 299
Study 22691922 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-soya blend (CSB) 71 g daily for 12 weeks
Number of subjects: 299
Study 22691922 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control)
Number of subjects: 299
Study 20168217 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 81
Study 20168217 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 81
Study 17613573 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A + additional physiotherapy
Number of subjects: 38
Study 17613573 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A
Number of subjects: 38
Study 16288095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-arm clinic and home-based intervention using nurse case management and community health workers
Number of subjects: 728
Study 12399697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish, containing 1% chlorhexidine and 1% thymol; applied on two separate occasions to all tooth surfaces at an interval of 3‐4 days.
Number of subjects: 18
Study 12399697 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsodyl gel, containing 1% chlorhexidine; applied for 3 x 5 min in individual applicators on 2 consecutive days.
Number of subjects: 18
Study 12399697 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish; applied on two separate occasions to all tooth surfaces at an interval of 3‐4 days.
Number of subjects: 18
Study 9950660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 0
Study 9950660 — intervention group
Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0
Study 9950660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0
Study 9950660 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study 7555557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI, low-carbohydrate breakfast (41 g carbohydrate)
Number of subjects: 8
Study 7555557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI, low-carbohydrate breakfast (41 g carbohydrate)
Number of subjects: 8
Study 7555557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI, high-carbohydrate breakfast (84 g carbohydrate)
Number of subjects: 8
Study 7555557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI, high-carbohydrate breakfast (84 g carbohydrate)
Number of subjects: 8
Study 1873936 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (1.1 +/- 0.3 g/kg/day)
Number of subjects: 24
Study 1873936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.7 +/- 0.1 g/kg/day)
Number of subjects: 24
Study 6352788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Number of subjects: 51
Study 6352788 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 51
Study 30419989 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (20-50 mg/d)
Number of subjects: 552
Study 29631444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle train intervention (BTI)
Number of subjects: 54
Study 29631444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 26809842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg day-1
Number of subjects: 201
Study 26809842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 25304843 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19
Study 25304843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22414837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic mixing method
Number of subjects: 60
Study 22414837 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mixing method
Number of subjects: 60
Study 22414837 — intervention group
Group type: EXPERIMENTAL
Intervention: Trituration mixing method
Number of subjects: 60
Study 19906761 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus Epirubicin 75 mg/m² (DE)
Number of subjects: 272
Study 19906761 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² plus Capecitabine 950 mg/m² (DC)
Number of subjects: 272
Study 19906761 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Epirubicin (DE)
Number of subjects: 272
Study 19906761 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus Capecitabine (DC)
Number of subjects: 272
Study 17915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only group (3 sessions of 60 minutes per week)
Number of subjects: 0
Study 17915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and cognitive training group (2 sessions of 60 minutes exercise and 1 session of 60 minutes cognitive training per week)
Number of subjects: 0
Study 17915035 — intervention group
Group type: COMPARATOR
Intervention: No-training control group (contacted every 4 weeks)
Number of subjects: 0
Study 16157124 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐alpha hydroxyprogesterone caproate (17‐OHP caproate)
Number of subjects: 459
Study 12174530 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activities (formal)
Number of subjects: 594
Study 12174530 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured physical activities (nonformal)
Number of subjects: 594
Study 12174530 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 594
Study 12174530 — intervention group
Group type: COMPARATOR
Intervention: Low activity group
Number of subjects: 594
Study 12174530 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal physical activities
Number of subjects: 594
Study 12174530 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal physical activities
Number of subjects: 594
Study 12174530 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity groups (girls)
Number of subjects: 594
Study 9974404 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIIa generation in the pericardium
Number of subjects: 12
Study 9974404 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin F1+2 levels in the pericardium
Number of subjects: 12
Study 9974404 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-antithrombin (TAT) levels in the pericardium
Number of subjects: 12
Study 9974404 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of factor VIIa, F1+2, and TAT levels
Number of subjects: 12
Study 9974404 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin levels
Number of subjects: 12
Study 7588500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) consumed occasionally (once a week)
Number of subjects: 14
Study 7588500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) consumed regularly (every day)
Number of subjects: 14
Study 7588500 — intervention group
Group type: COMPARATOR
Intervention: Comparison of breath hydrogen excretion between occasional and regular consumption of FOS
Number of subjects: 14
Study 2298594 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group attendance (n = 25)
Number of subjects: 55
Study 2298594 — intervention group
Group type: COMPARATOR
Intervention: Bedside support from nurses and health professionals (n = 30)
Number of subjects: 55
Study 344088 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 120
Study 344088 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 to 750 mg daily
Number of subjects: 120
Study 344088 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg daily
Number of subjects: 120
Study 344088 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg daily
Number of subjects: 120
Study 31285303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1231
Study 31285303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1231
Study 28411872 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg risankizumab
Number of subjects: 121
Study 28411872 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg risankizumab
Number of subjects: 121
Study 28411872 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab (pooled 200 mg and 600 mg)
Number of subjects: 121
Study 28411872 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study 28411872 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab (all doses)
Number of subjects: 121
Study 26640708 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic Manual Therapy (OMT)
Number of subjects: 36
Study 26640708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling and Stretching (DN-S)
Number of subjects: 36
Study 26640708 — intervention group
Group type: COMPARATOR
Intervention: Soft Tissue Techniques (STT)
Number of subjects: 36
Study 23702498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided platelets rich plasma (PRP) injection and conservative treatment
Number of subjects: 30
Study 23702498 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative treatment only
Number of subjects: 30
Study 22334465 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19335746 — intervention group
Group type: EXPERIMENTAL
Intervention: ET receptor antagonists (ETRAs)
Number of subjects: 0
Study 19335746 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ET(A) blockade
Number of subjects: 0
Study 19335746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective ET(A)/ET(B) blockade
Number of subjects: 0
Study 17615011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 0
Study 15156869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (50 microg/mL ozone)
Number of subjects: 12
Study 15156869 — intervention group
Group type: COMPARATOR
Intervention: Control (autohemotherapy with exposure to oxygen)
Number of subjects: 12
Study 11418308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines (3 weekly injections, followed by monthly injections for 5 months)
Number of subjects: 69
Study 11418308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines
Number of subjects: 69
Study 9554348 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6
Study 9554348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8147523 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 150
Study 8147523 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask without insertion aid
Number of subjects: 150
Study 8147523 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask with insertion aid
Number of subjects: 150
Study 2905145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg kg‐1
Number of subjects: 57
Study 2905145 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.06 mg kg‐1
Number of subjects: 57
Study 29726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation with OKA ≤ 23° (group U)
Number of subjects: 20
Study 29726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation with OKA > 23° (group O)
Number of subjects: 20
Study 29726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation (both groups)
Number of subjects: 20
Study 27404222 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of arterial hyperoxemia during CPB
Number of subjects: 298
Study 27404222 — intervention group
Group type: COMPARATOR
Intervention: Usual care during CPB
Number of subjects: 298
Study 24961892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome (CoCr) and ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 80
Study 24961892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome (CoCr) and cross-linked polyethylene (XLPE)
Number of subjects: 80
Study 24961892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxinium and ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 80
Study 24961892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxinium and cross-linked polyethylene (XLPE)
Number of subjects: 80
Study 23770175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1664
Study 23770175 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1664
Study 19358746 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in cognitive behaviour therapy (CBT)
Number of subjects: 34
Study 19358746 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 34
Study 18178463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10
Study 18178463 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 10
Study 16313107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 90
Study 16313107 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (Control group 1)
Number of subjects: 90
Study 16313107 — intervention group
Group type: COMPARATOR
Intervention: Marzulene‐s granule (Control group 2)
Number of subjects: 90
Study 12704002 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere single agent (75 mg/m2 iv 1 hour)
Number of subjects: 34
Study 12704002 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere (60 mg/m2 iv 1 hour) plus Adriamycin (50 mg/m2 iv 1 hour)
Number of subjects: 34
Study 10492632 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg of Megestrol Acetate (MA) daily for 12 weeks
Number of subjects: 255
Study 10492632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 8740271 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated essential fatty acids
Number of subjects: 25
Study 8740271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1759762 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ampicillin before insertion of the chest tube
Number of subjects: 188
Study 1759762 — intervention group
Group type: COMPARATOR
Intervention: Additional antibiotic prophylaxis for as long as the drain was in place
Number of subjects: 188
Study 6125678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantoux test (10 IU PPD-Weybridge)
Number of subjects: 200
Study 6125678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tine test
Number of subjects: 200
Study 6125678 — intervention group
Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 200
Study 6125678 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test (repeated)
Number of subjects: 200
Study 30997917 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE ε4 status
Number of subjects: 1300
Study 28634219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high-dose N-acetylcysteine (29 g over 2 days) with low-dose nitroglycerin (7.2 mg over 2 days)
Number of subjects: 112
Study 28634219 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-dose nitroglycerin
Number of subjects: 112
Study 26648084 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tabalumab (0.01, 0.04, 0.125, 0.5, 2.0, and 8.0 mg/kg for RA; 0.125 or 2.0 mg/kg for SLE)
Number of subjects: 41
Study 26648084 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tabalumab (20 mg)
Number of subjects: 41
Study 26648084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tabalumab (10 mg)
Number of subjects: 41
Study 25241196 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD‐PS + copd‐6
Number of subjects: 8770
Study 25241196 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD‐PS
Number of subjects: 8770
Study 25241196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 8770
Study 21334099 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals with high amyloid burden
Number of subjects: 0
Study 21334099 — intervention group
Group type: COMPARATOR
Intervention: Young subjects
Number of subjects: 0
Study 21334099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus activity across groups
Number of subjects: 0
Study 19410975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented infant formula
Number of subjects: 81
Study 19410975 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented formula (Control)
Number of subjects: 81
Study 17434505 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 136
Study 17434505 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 136
Study 15459210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 28 days
Number of subjects: 301
Study 15459210 — intervention group
Group type: COMPARATOR
Intervention: Comparator (vinorelbine 30 mg/m² weekly or mitomycin C 10 mg/m² day 1 and every 28 days plus vinblastine 5 mg/m² day 1, day 14, day 28, and day 42)
Number of subjects: 301
Study 15459210 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD in anthracycline-naïve patients
Number of subjects: 301
Study 15459210 — intervention group
Group type: COMPARATOR
Intervention: Comparator in anthracycline-naïve patients
Number of subjects: 301
Study 11448376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/d) + Clonazepam (0.5 mg, 3 times daily for 4 weeks)
Number of subjects: 50
Study 11448376 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (100 mg/d) + Placebo Clonazepam
Number of subjects: 50
Study 9602960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (25 mg)
Number of subjects: 0
Study 9602960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (50 mg)
Number of subjects: 0
Study 9602960 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (100 mg)
Number of subjects: 0
Study 9602960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7927548 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women
Number of subjects: 105
Study 7927548 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with pregnancy induced hypertension (PIH)
Number of subjects: 105
Study 7927548 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women and women with PIH
Number of subjects: 105
Study 2682431 — intervention group
Group type: EXPERIMENTAL
Intervention: oxpentifylline (Hoechst UK)
Number of subjects: 30
Study 2682431 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 1096595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-vitamin supplement from infancy
Number of subjects: 1500
Study 1096595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated water
Number of subjects: 1500
Study 1096595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-vitamin supplement from age 4
Number of subjects: 1500
Study 1096595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study 31924258 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory driven web-application
Number of subjects: 20
Study 31924258 — intervention group
Group type: COMPARATOR
Intervention: Standard website
Number of subjects: 20
Study 29788253 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Exercise (3-month intervention with about 5 face-to-face physical therapy sessions integrated with an online application)
Number of subjects: 208
Study 29788253 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (conducted according to Dutch physical therapy guidelines)
Number of subjects: 208
Study 29788253 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Exercise
Number of subjects: 208
Study 29788253 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Exercise and Usual physical therapy
Number of subjects: 208
Study 26249791 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTOMED diet
Number of subjects: 125
Study 26249791 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTOMED diet plus AISA d‐Limonene
Number of subjects: 125
Study 26249791 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTOMED diet plus VSL#3 probiotic blend
Number of subjects: 125
Study 26249791 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTOMED diet with AISA d‐Limonene supplementation
Number of subjects: 125
Study 24560487 — intervention group
Group type: EXPERIMENTAL
Intervention: BIRIP (irinotecan 60mg/m² plus cisplatin 30mg/m², every 2 weeks)
Number of subjects: 130
Study 24560487 — intervention group
Group type: COMPARATOR
Intervention: irinotecan alone (irinotecan 150mg/m², every 2 weeks)
Number of subjects: 130
Study 24560487 — intervention group
Group type: EXPERIMENTAL
Intervention: BIRIP
Number of subjects: 130
Study 24560487 — intervention group
Group type: COMPARATOR
Intervention: irinotecan alone
Number of subjects: 130
Study 22251035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 60
Study 22251035 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal(®))
Number of subjects: 60